Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells

Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Bin, Fujimoto, Naohiro, Kobayashi, Mizuki, Matsumoto, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195320/
https://www.ncbi.nlm.nih.gov/pubmed/22111007
http://dx.doi.org/10.1155/2012/989214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195320/
https://www.ncbi.nlm.nih.gov/pubmed/22111007
http://dx.doi.org/10.1155/2012/989214

Ejemplares similares